Explore University of Melbourne licensing opportunities and research discoveries that could help solve industry’s big challenges.
Available for licensing
-
ADMiER
ADMiER reduces the time required to diagnose dry eye disease from an estimated 18 minutes of chair-time to just three minutes. Help us enhance clinical outcomes for patients with more accurate disease characterisation through licensing.
-
Bio-Dash
Accelerate the development of this practically-focused wellbeing program through licensing or direct investment. Bio-Dash is a practical and engaging wellbeing program that equips individuals to self-manage their mental health using evidence-based strategies and personal feedback.
-
Broad and ultra-potent anti-HIV-1 antibodies
Accelerate the development of broad and ultra-potent anti-HIV-1 antibodies through licensing or direct investment.
-
Chip design methodology
The chip design methodology improves cybersecurity of low-power devices like smart cards. Partner with us to accelerate development through licensing or co-development opportunities.
-
COVID-19 vaccine platform
A COVID-19 vaccine platform that enables rapid production of second-generation vaccines against SARS-CoV-2 variants of concern has been developed by University of Melbourne researchers.
-
Foundations of Wellbeing
Accelerate the development of this online wellbeing program for the workplace through licensing or direct investment. This evidence-based online wellbeing program is designed to improve employee engagement, enjoyment and productivity at work.
-
Left Write Hook
Left Write Hook equips adult survivors of sexual violence to actively take back power through an evidence-based program blending creative writing and boxing. Accelerate the development of this recovery empowerment program for sexual abuse survivors through licensing or direct investment.
-
Live rabies vaccine
Rabies is usually fatal in people once symptoms appear. University of Melbourne researchers have identified a strategy for a safe live rabies vaccine that is able to overcome the limitations of inactivated vaccines. Partner with us to accelerate the development of therapeutic or prophylactic rabies vaccines.
-
Monoclonal antibodies against COVID-19
New SARS-CoV-2 variants have rendered ineffective most US Food and Drug Administration-approved COVID-19 antibody treatments and reduced vaccine efficacy.
-
New targeting strategy for lupus erythematosus
Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.
-
Non-invasive biomarker for diabetic neuropathy
A biomarker produced in tears could be used in early diagnosis and monitoring of neuropathy in people with diabetes, in place of current invasive or difficult-to-access diagnostic methods.
-
Predicting landslides
A new technology that can predict landslides up to 15 days in advance has proved successful using sample datasets. It is now ready for further validation and software development.
-
Second-generation COVID-19 vaccine
First-generation COVID-19 vaccines have reduced efficacy against the emerging variants of SARS-CoV-2.
-
Star-shaped polypeptides
Partner with us to speed up the development of Structurally Nanoengineered Antimicrobial Peptide Polymers (or SNAPP) anti-bacterial technology.
-
Tissue-engineered corneal endothelium graft
Partner with us to license graft technology that treats corneal dysfunction.
-
Ultra-thin single crystal diamond membrane
Partner with us to accelerate the development and validation of the fabrication method for single crystal diamond membranes, through licensing and/or co-development.
-
Negotiating a licence with the University
Does your organisation see an opportunity to develop or use our research discoveries? Find out how to access those through a licensing agreement.
-
Intellectual Property (IP) principles and agreements
Collaboration can create new IP. Discover the principles that guide how the University manages IP with its partners.